MedTrace Logo

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

NCT06768931 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2026-04-01

No results posted yet for this study

Summary

To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer

Conditions

  • Breast Cancer
  • Triple Negative Breast Cancer (TNBC)
  • Early Stage Breast Cancer
  • Immunotherapy
  • Probiotic

Interventions

OTHER

Biolosion (oral probiotic compound preparation)

Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2030-01-08
Completion
2035-02-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06768931 on ClinicalTrials.gov